Monthly Archive: November 2016

Nov 23

Press Release: Osimertinib Efficacy Against Intracranial EGFRvIII-Positive GBMs

The Glioblastoma Drug Discovery Group announces that osimertinib significantly prolongs the survival of immunocompromised mice bearing intracranial EGFRvIII-positive glioblastoma! These data warrant the commencement of studies designed to test osimertinib’s safety and efficacy in GBM patients.

Nov 23

Press Release: Dr. Steven Keating, Our New Advisor

The Glioblastoma Drug Discovery Group is proud to have brain tumor survivor, Dr. Steven Keating, Ph.D., as a volunteer advisor. Dr. Keating is a strong proponent of curiosity and open patient data, having discovered his own brain tumor during a voluntary academic scan. Since Dr. Keating had a successful brain tumor removal surgery via awake …

Continue reading »